BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

ADC drugs have the advantages of highly specific targeting of antibody and anti cancer activity of cytotoxin. ADC shave developed rapidly as tumor therapeu...

March 16, 2023 | News

FDA approves Abbisko Therapeutics' Pimicotinib for Phase III clinical trial

This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib （ABSK021）was granted BTD by FDA and CDE, discovered a...

March 16, 2023 | News

Simcere Zaiming partners with Merck for SIM0235 clinical trial in advanced tumors and lymphoma

Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an in...

March 15, 2023 | News

Revolutionizing Drug Development: How AI is Reducing Time and Costs of Bringing New Treatments to Market

The development of new drugs is a lengthy and costly process that can take several years and cost billions of dollars. However, the emergence of artificial...

March 10, 2023 | Opinion

Estrella Biopharma's ARTEMIS® T Cell Therapy EB103 IND Cleared by FDA for B-Cell Lymphomas Clinical Trial

Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transfo...

March 09, 2023 | News

Debiopharm Acquires Global Rights for Novo Nordisk's USP1 Inhibitor Development.

Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow's standard-of-care treatments to cure can...

March 02, 2023 | News

Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets

Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltr...

February 22, 2023 | News

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Prior to this approval from the US FDA, Biosyngen's BRG01 was granted IND by China CDE on December 14th, 2022. In addition, China CDE has acknowledged...

February 18, 2023 | News

Inventia Life Science collaborates with MSD to develop 3D advanced cell models

Collaboration to develop 3D in vitro models of the brain for the discovery of therapeutic candidates using Inventia's novel 3D cell culture platform, RASTR...

February 16, 2023 | News

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CR...

February 15, 2023 | News

BioDuro-Sundia Expands Drug Discovery Capacity and Capability

Dr. Xiang Li, President of BioDuro-Sundia Drug Discovery, explains: “At BioDuro-Sundia, we are fully invested in our clientele and pro-actively plann...

February 15, 2023 | News

Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial

BA1106 is the first investigational anti-CD25 antibody to start clinical trials in China for treating solid tumors. Focusing on key therapeutic a...

February 13, 2023 | News

Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary IgA Nephropathy

This demonstrates the urgent unmet medical needs for Nefecon, as Everest also received Priority Review status for the New Drug Application (NDA) of Nefecon...

February 10, 2023 | News

Microba and BioAgilytix announce partnership to fast-track therapeutic delivery

Enables innovators to confidently leverage microbiome endpoints in clinical trials Delivers superior outcomes for clients at each stage of the d...

February 09, 2023 | News

Stay Connected